Agilent Technologies (A) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
23 Jan, 2026Executive summary
Annual meeting scheduled for March 18, 2026, to elect four directors, approve executive compensation, ratify the auditor, and vote on declassifying the Board over three years.
Board recommends all proposals, including declassifying the Board in response to strong shareholder support.
Company achieved 6.7% revenue growth, 3.2% GAAP EPS growth, and 5.7% non-GAAP EPS growth in FY2025.
Executive compensation is heavily performance-based, with 82–91% of pay at risk, and strong shareholder support for pay practices.
Voting matters and shareholder proposals
Four proposals: election of four directors, advisory vote on executive compensation, ratification of PwC as auditor, and amendment to declassify the Board.
Board recommends voting FOR all proposals.
Declassification of the Board to be phased in from 2027 to 2029, with all directors elected annually starting in 2029.
Shareholder engagement led to the declassification proposal after 65% of shareholders were consulted.
Board of directors and corporate governance
Board consists of eleven directors with a mix of tenures and diverse backgrounds.
Ten of eleven directors are independent; independent Chairperson leads the Board.
Board committees: Audit and Finance, Compensation, Nominating/Corporate Governance, and Executive.
Annual Board and committee self-assessments, with regular refreshment and focus on diversity and skills.
Proxy access allows shareholders (3% ownership for 3 years) to nominate directors.
Latest events from Agilent Technologies
- Q1 FY26 revenue rose 7% to $1.80B, non-GAAP EPS up 4%, and FY26 guidance was raised.A
Q1 20263 Mar 2026 - Strong growth, innovation, and disciplined strategy support positive outlook for the year.A
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Key votes include director elections, auditor ratification, and Board declassification.A
Proxy Filing6 Feb 2026 - Board seeks approval for director elections, pay, auditor, and Board declassification amid strong governance.A
Proxy Filing6 Feb 2026 - Q2 met expectations, but slower recovery and China headwinds led to a guidance cut.A
Jefferies Global Healthcare Conference31 Jan 2026 - Q3 revenue beat guidance, net income surged, and full-year outlook was raised amid market challenges.A
Q3 202423 Jan 2026 - FY26 targets 4–6% core growth, margin gains, and $7.3B–$7.4B revenue via Ignite and innovation.A
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Q4 non-GAAP EPS up 6% to $1.46; FY25 revenue and EPS growth expected.A
Q4 202412 Jan 2026 - Ignite strategy drives 5%-7% growth, margin expansion, and leadership in high-growth markets.A
Investor Day 202411 Jan 2026